je.st
news
Tag: therapy
Audentes Therapeutics Acquires Cardiac Gene Therapy Company Cardiogen Sciences
2015-09-02 07:53:29| drugdiscoveryonline News Articles
Audentes Therapeutics, Inc., a biotechnology company committed to the development and commercialization of gene therapy products for patients with serious, rare diseases, recently announced the acquisition of Cardiogen Sciences, Inc., a biotechnology company focused on the discovery and development of adeno-associated virus(AAV) gene therapy products for rare, inherited arrhythmogenic diseases
Tags: company
sciences
therapy
gene
RetroSense Therapeutics' Lead Gene Therapy Candidate Gets FDA Clearance To Proceed To First-In-Human Clinical Trials
2015-09-02 07:40:59| drugdiscoveryonline News Articles
RetroSense Therapeutics LLC, a privately-held biopharmaceutical company, recently announced the Company’s Investigational New Drug (IND) application for RST-001 received clearance from the United States Food and Drug Administration (FDA)
Tags: lead
clinical
therapy
candidate
Viamet And Mycoses Study Group Education & Research Consortium Establish Collaboration To Advance A Novel Therapy For Cryptococcal Meningitis
2015-09-02 07:24:07| drugdiscoveryonline News Articles
Viamet Pharmaceuticals, Inc. and the Mycoses Study Group Education & Research Consortium (MSGERC) recently announced the establishment of a strategic collaboration to advance a novel therapy for cryptococcal meningitis and other life-threatening fungal infections
Tags: for
group
research
education
What is gene therapy?
2015-08-31 13:30:50| Extremetech
Gene therapy is one of the hottest topics in medicine, but how does it work, and what can it really do?
FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA (pembrolizumab), Mercks Anti-PD-1 Therapy, for First-Line Treatment of Advanced Melanoma, and Grants Priority Review
2015-08-18 14:00:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. Merck Provides Additional Update: FDA Extends Action Date for Additional sBLA in Ipilimumab-Refractory Advanced Melanoma KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License Application (sBLA) for KEYTRUDA (pembrolizumab), Mercks anti-PD-1 therapy. Merck is seeking approval for KEYTRUDA, at the currently approved dose of 2 mg/kg every three weeks, for the first-line treatment of unresectable or metastatic melanoma patients. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orInvestors:Justin Holko, 908-740-1879An Phan, 908-255-6325 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: advanced
review
application
license
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] next »